Keros Therapeutics (KROS) Research & Development (2019 - 2026)

Keros Therapeutics (KROS) has reported Research & Development for 8 consecutive years, with $22.3 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Research & Development fell 48.67% year-over-year to $22.3 million; the trailing twelve-month figure through Jun 2026 stood at $103.3 million (down 44.8% YoY), and the FY2025 full-year result was $129.6 million, down 25.33% from the prior year.
• Research & Development climbed to $22.3 million in Q2 2026 per KROS's latest filing, from $17.9 million in the prior quarter.
• Across five years, Research & Development topped out at $49.2 million in Q3 2024 and bottomed at $17.9 million in Q4 2025.
• Historically, Research & Development has averaged $32.2 million across 5 years, with a median of $32.5 million in 2023.
• The sharpest annual moves came in 2022 and 2025: Research & Development soared 133.21% in 2022, then plunged 60.75% in 2025.
• Over 5 years, Research & Development stood at $24.9 million in 2022, then soared by 50.77% to $37.5 million in 2023, then rose by 21.71% to $45.6 million in 2024, then slumped by 60.75% to $17.9 million in 2025, then increased by 24.67% to $22.3 million in 2026.
• According to Business Quant data, Research & Development over the past three periods registered $22.3 million, $17.9 million, and $19.5 million for Q2 2026, Q4 2025, and Q3 2025 respectively.